Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient.
Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient.
复制标题
DOI：
10.1111/tid.12545
复制
发表时间：
2016-08
期刊：
影响因子：
--
通讯作者：
Doyle AM
中科院分区：
文献类型：
--
作者：
Lee DH;Malat GE;Bias TE;Harhay MN;Ranganna K;Doyle AM
多洛替格列韦是实体器官移植后人类免疫缺陷病毒(HIV)感染患者的首选抗逆转录病毒药物。它具有强大的抗逆转录病毒活性，不与钙调神经磷酸酶抑制剂相互作用。我们描述了一例HIV感染的肾移植患者，在开始应用多洛替格列韦后，注意到其血清肌酐升高。起初怀疑是急性排斥反应，但后来这一发现被归因于多洛替格列韦抑制肌酐分泌。我们建议，对于照顾HIV阳性肾移植受者的提供者来说，意识到多洛替格韦的这种潜在作用是重要的，以防止可能不必要的测试。
Dolutegravir is a preferred antiretroviral drug for human immunodeficiency virus (HIV)-infected patients following solid organ transplantation. It has potent antiretroviral activity and does not interact with calcineurin inhibitors. We describe a case of an HIV-infected kidney transplant patient, who was noted to have a rising serum creatinine following initiation of dolutegravir. At first an acute rejection episode was suspected, but this finding was later attributed to inhibition of creatinine secretion by dolutegravir. We suggest that an awareness of this potential effect of dolutegravir is important for providers who take care of HIV-positive kidney transplant recipients, in order to prevent potentially unnecessary testing.
登录
查看更多内容
影响因子：
13.6
作者：
Locke, Jayme E.;Mehta, Shikha;Segev, Dorry L.
通讯作者：
Segev, Dorry L.
影响因子：
158.5
作者：
Walmsley, Sharon L.;Antela, Antonio;Nichols, Garrett
通讯作者：
Nichols, Garrett
影响因子：
3.4
作者：
Koteff, Justin;Borland, Julie;Piscitelli, Stephen C.
通讯作者：
Piscitelli, Stephen C.
影响因子：
6.2
作者：
van Maarseveen, Erik M.;Crommelin, Heleen A.;van Zuilen, Arjan D.
通讯作者：
van Zuilen, Arjan D.
DOI：
10.1111/ajt.13220
发表时间：
2015-08
期刊：
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子：
--
作者：
Locke JE;Reed RD;Mehta SG;Durand C;Mannon RB;MacLennan P;Shelton B;Martin MY;Qu H;Shewchuk R;Segev DL
通讯作者：
Segev DL